RT Journal Article
T1 Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?
A1 Esteve-Pastor, María Asunción
A1 García-Fernández, Amaya
A1 Macías, Manuel
A1 Sogorb, Francisco
A1 Valdés, Mariano
A1 Roldán, Vanessa
A1 Muñiz, Javier
A1 Badimon, Lina
A1 Roldán, Inmaculada
A1 Bertomeu-Martínez, Vicente
A1 Cequier, Ángel
A1 Lip, Gregory Y H
A1 Anguita, Manuel
A1 Marín, Francisco
A1 FANTASIIA Investigators, 
AB Several bleeding risk scores have been validated in patients with atrial fibrillation (AF). The ORBIT score has been recently proposed as a simple score with the best ability to predict major bleeding. The present study aimed to test the hypothesis that the ORBIT score was superior to the HAS-BLED score for predicting major bleeding and death in "real world" anticoagulated AF patients. We analyzed the predictive performance for bleeding and death of 406 AF patients who underwent 571 electrical cardioversion procedures and 1,276 patients with permanent/persistent AF from the FANTASIIA registry. In the cardioversion population, 21 patients had major bleeding events and 26 patients died. The predictive performance for major bleeding of HAS-BLED and ORBIT were not significantly different (c-statistics 0.77 (95% CI 0.66-0.88) and 0.82 (95% CI 0.77-0.93), respectively; P=0.080). For the FANTASIIA population, 46 patients had major bleeding events and 50 patients died. The predictive performances for major bleeding of HAS-BLED and ORBIT were not significantly different (c-statistics 0.63 (95% CI 0.56-0.71) and 0.70 (95% CI 0.62-0.77), respectively; P=0.116). For death, the predictive performances of HAS-BLED and ORBIT were not significantly different in both populations. The ORBIT score categorized most patients as "low risk". Despite the original claims in its derivation paper, the ORBIT score was not superior to HAS-BLED for predicting major bleeding and death in a "real world" oral anticoagulated AF population. (Circ J 2016; 80: 2102-2108).
YR 2016
FD 2016-08-24
LK http://hdl.handle.net/10668/10389
UL http://hdl.handle.net/10668/10389
LA en
DS RISalud
RD Apr 7, 2025